Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
IMPORTANT: This compound is currently on the World Anti-Doping Agency (WADA) prohibited list. Competitive athletes face sanctions for use including in retirement testing programs. Verify current WADA status with your sport's governing body before any research involvement.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. The compounds discussed are research chemicals that are not FDA-approved for human use. Always consult a licensed healthcare professional before considering any peptide protocol. WolveStack has no medical staff and does not diagnose, treat, or prescribe. See our full disclaimer.
Hexarelin is a synthetic growth hormone secretagogue—a potent ghrelin receptor agonist that triggers the pituitary gland to release growth hormone in a robust, pulsatile pattern. Developed in the 1990s by Mediolanum Farmaceutici, it was originally investigated as a therapeutic for GH deficiency and HIV-related wasting. In the research peptide community, Hexarelin is known as one of the most potent GH releasers available, capable of producing larger GH pulses than ipamorelin, GHRP-2, or GHRP-6 at comparable doses. However, this potency comes with a notable trade-off: Hexarelin raises cortisol and prolactin more significantly than other GHRPs and exhibits rapid desensitization—tachyphylaxis—meaning responsiveness declines substantially after 2–4 weeks of continuous use.
Research context only. The compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Quick Answer: Hexarelin is a potent GH secretagogue producing stronger GH pulses than most alternatives, but at the cost of elevated cortisol/prolactin and rapid desensitization. Typical research dosage is 100–200 mcg subcutaneous 2–3 times daily. Most protocols last 2–4 weeks due to tachyphylaxis, followed by 4–8 week breaks to restore receptor sensitivity.
What Is Hexarelin?
Hexarelin (also known as Examorelin) is a six-amino-acid peptide ([His]-D-[2-methyl-Trp]-Ala-Trp-D-Phe-Lys-NH₂) that functions as a potent agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), commonly known as the ghrelin receptor. Unlike endogenous ghrelin, which is produced in the stomach and released during fasting, Hexarelin is a synthetic compound that mimics ghrelin's signaling at GHS-R1a, causing the pituitary somatotroph cells to release growth hormone.
Hexarelin was developed as a therapeutic agent for conditions involving GH deficiency (adult-onset GH deficiency, HIV-related wasting) and was studied in clinical trials in the late 1990s and early 2000s. While it never reached the pharmaceutical market in most countries, it gained widespread use in research contexts and the performance enhancement community due to its exceptional potency as a GH releaser.
The defining characteristics of Hexarelin are: (1) robust GH release magnitude—greater than ipamorelin or older GHRPs at equivalent molar doses; (2) rapid loss of efficacy (desensitization) within 2–4 weeks; and (3) off-target hormonal effects, particularly cortisol and prolactin elevation. These properties make it a specialized tool suited to short, intensive GH stimulation protocols rather than chronic use.
How Does Hexarelin Work?
Hexarelin's mechanism is GHS-R1a agonism. The ghrelin receptor is expressed primarily in the anterior pituitary (somatotroph cells), hypothalamus, and stomach. When Hexarelin binds GHS-R1a on pituitary somatotrophs, it triggers a rapid intracellular calcium mobilization cascade, leading to GH granule exocytosis and a pulsatile GH release that mimics the natural GH pulse.
Mechanism cascade:
- GHS-R1a receptor binding (primary signal)
- IP3 and DAG pathway activation
- Calcium influx and PKC stimulation
- GH granule release from somatotrophs
- GH pulse peaks 15–30 minutes post-injection
Why Hexarelin is so potent: Hexarelin has higher receptor affinity and selectivity for GHS-R1a compared to ipamorelin, and its binding characteristics produce more forceful and sustained GH release. Studies comparing GH AUC (area under the curve—total GH released) show Hexarelin producing approximately 50–100% greater GH pulses than ipamorelin at equimolar doses.
The cortisol and prolactin elevation: Hexarelin's GHS-R1a agonism is not perfectly selective; it also stimulates corticotroph cells (ACTH, leading to cortisol elevation) and lactotroph cells (prolactin elevation) more substantially than ipamorelin. This occurs at all Hexarelin doses and is dose-dependent.
Desensitization (tachyphylaxis): Continuous or frequent GHS-R1a stimulation leads to rapid receptor downregulation and signal attenuation. The GH response to Hexarelin declines by 50–80% within 2–4 weeks of daily use. This loss of efficacy is the most significant limitation and necessitates cycling and off-periods.
Interestingly, Hexarelin was also discovered to have cardioprotective effects in preclinical studies, possibly through CD36 activation and improved cardiac mitochondrial metabolism. This finding, though not clinically validated, distinguishes it from other GHRPs.
What Does the Research Show?
Hexarelin has been extensively characterized in clinical and preclinical research, particularly in the 1990s and 2000s when it was under development as a therapeutic agent.
Key research findings:
- GH release magnitude: Multiple studies confirmed Hexarelin as one of the most potent synthetic GH secretagogues, producing larger AUC values than GHRP-2, GHRP-6, ipamorelin, and MK-0677. A single 2 mcg/kg IV bolus in humans produced GH peaks of 20–40 ng/mL.
- Cortisol and prolactin elevation: Clinical trials documented dose-dependent rises in both cortisol and prolactin. At high doses, cortisol elevation was significant and concerning for long-term therapeutic use.
- Desensitization kinetics: Repeated dosing studies showed rapid loss of GH response. The ED50 (the dose producing 50% of maximal response) increased substantially over a 2–4 week dosing period, indicating receptor downregulation.
- Cardioprotection: Preclinical studies suggested Hexarelin activates CD36 (a cardiac metabolic sensor) and improves myocardial fatty acid oxidation, potentially benefiting heart function. This finding did not lead to clinical translation.
- IGF-1 elevation: Chronic Hexarelin dosing did raise serum IGF-1 levels, but less robustly than would be expected from the large GH pulses, likely due to the high cortisol and prolactin also present.
Formal human efficacy trials for body composition or muscle gain were never conducted, so evidence for real-world anabolic benefits is limited to animal models and community reports.
The combination of potency and hormonal side effects, along with rapid desensitization, made Hexarelin unsuitable for the chronic therapeutic use that was originally envisioned, explaining why it was discontinued in development.
Hexarelin vs. Other GH Secretagogues
Understanding where Hexarelin stands relative to other GHRPs helps clarify its niche and limitations:
| Secretagogue | GH Potency | Cortisol/Prolactin | Desensitization | Best For |
|---|---|---|---|---|
| Hexarelin | Highest | Elevated (concern) | Rapid (2–4 wks) | Short, intense cycles |
| GHRP-2 | Very High | Elevated (moderate) | Moderate (4–8 wks) | Potent GH release, short use |
| GHRP-6 | Very High | Moderate | Moderate | GH + appetite stimulation |
| Ipamorelin | Moderate-High | Minimal | Slow (8–12+ wks) | Clean GH, long-term use |
| MK-0677 (Ibutamoren) | Moderate | Minimal | Minimal (no DAC) | Oral, daily use |
Hexarelin vs. Ipamorelin specifically: Hexarelin produces substantially larger GH pulses but elevates cortisol and prolactin meaningfully, whereas ipamorelin's GH output is slightly lower but far cleaner hormonally. Hexarelin desensitizes rapidly, limiting use to 2–4 weeks, while ipamorelin can be used for 8–12+ weeks. For researchers seeking maximal GH release in a brief window, Hexarelin excels. For sustained, clean GH elevation, ipamorelin is superior.
Hexarelin vs. GHRP-2/GHRP-6: Hexarelin is more potent than GHRP-2 and GHRP-6 on a per-molar basis, and exhibits faster desensitization. GHRP-6 causes intense hunger, which Hexarelin does not. GHRP-2 is a middle ground—less potent than Hexarelin but potentially less prone to rapid desensitization.
Dosage & Administration
| Protocol | Dose | Frequency | Cycle |
|---|---|---|---|
| Conservative start | 50–100 mcg | 1x daily | 2–3 weeks, then 4–6 weeks off |
| Standard (moderate) | 100–150 mcg | 2x daily | 2–4 weeks, then 4–8 weeks off |
| Enhanced (aggressive) | 150–200 mcg | 2–3x daily | 2–4 weeks max, then 6–8 weeks off |
| Research maximum | 200+ mcg | 3x daily | 2–3 weeks (short burst) |
Route: Subcutaneous injection only. Intramuscular and intravenous routes are used in research but SQ is standard in community protocols.
Timing: Best administered on an empty stomach for maximal GH response. Inject 30–60 minutes before training or sleep for synergistic effects. Multiple daily doses are spaced 6–8 hours apart.
Half-life: Approximately 30 minutes in circulation, with GH peak occurring 15–30 minutes post-injection. Despite short half-life, receptor signaling and downstream effects persist longer.
Critical cycling rule: Do not exceed 3–4 weeks of continuous use. The GH response declines steeply by week 4, making continued use ineffective. After use, take a minimum 4–6 week break to allow GHS-R1a receptors to recover sensitivity. Some researchers recommend 1 week on / 3 weeks off or 2 weeks on / 6–8 weeks off protocols to maintain some responsiveness.
Stacking: Some users combine Hexarelin with CJC-1295 (no DAC) for synergistic GH release, though this amplifies cortisol elevation. Others use Hexarelin in short bursts (2–3 weeks) followed by ipamorelin cycles to maintain ongoing GH stimulation while minimizing side effects.
Hexarelin loses efficacy rapidly. By week 3–4 of continuous use, GH response may drop 50–80%. Continuing beyond this window wastes the peptide. Strict adherence to cycling (2–4 weeks on, 4–8 weeks off minimum) is essential to maintain effectiveness and manage hormonal side effects.
Side Effects & Safety Profile
Hexarelin's side effect profile is more significant than ipamorelin's due to its broader receptor activation and potent hormonal effects. However, most side effects are manageable if use is limited to 2–4 week cycles.
Common side effects:
- Cortisol elevation: Dose-dependent and consistent. Clinical studies showed cortisol increases of 50–100% above baseline at moderate-to-high doses. This can manifest as mild anxiety, insomnia, or water retention. Mitigated by short cycle lengths.
- Prolactin elevation: Also dose and time-dependent. Can cause mild breast tissue sensitivity in males, lactation-like discharge in some cases (rare), or mood changes. Returns to baseline 2–4 weeks post-cycle.
- Water retention: More pronounced than with ipamorelin, attributable to elevated cortisol and GH. Usually resolves within 1–2 weeks of stopping.
- GH flu: Transient fatigue, joint aches, and mild malaise in the first 1–2 weeks from rapid GH elevation. Often resolves despite continuing use.
- Carpal tunnel syndrome (CTS): Rare but reported in some users with extended Hexarelin use, likely due to soft tissue swelling from high GH levels. Risk is low with short cycles.
- Appetite stimulation: Mild, mediated by ghrelin receptor activation. Much less intense than GHRP-6 but noticeable in some users.
Longer-term / high-dose concerns:
- Hypertension: Not directly caused by Hexarelin, but elevated cortisol can contribute to blood pressure elevation in susceptible individuals.
- Glucose dysregulation: Elevated cortisol and GH can impair glucose tolerance. Users should monitor fasting glucose if using for extended periods.
- Mood/anxiety: Elevated cortisol can trigger anxiety or mood lability in sensitive individuals. Risk is low with short cycles.
Safety monitoring: Baseline cortisol, prolactin, and glucose testing before starting is recommended. Repeat testing during the first week and at the end of a cycle helps assess individual sensitivity. Blood pressure monitoring is prudent, especially in those with hypertension history.
Contraindications: Hexarelin should be avoided in those with uncontrolled hypertension, active carpal tunnel syndrome, or those on medications that raise cortisol or prolactin. Consultation with a healthcare provider is mandatory.
Key Takeaways
- Hexarelin is one of the most potent GH secretagogues, producing larger pulses than ipamorelin, GHRP-2, and GHRP-6.
- It raises cortisol and prolactin more substantially than other GHRPs, necessitating careful monitoring and short cycle lengths.
- Rapid desensitization (loss of effect within 2–4 weeks) is the primary limitation; strict cycling is essential.
- Best suited to 2–4 week bursts of intense GH stimulation, not sustained long-term use.
- Typical dosage is 100–200 mcg SQ 1–3x daily, followed by 4–8 week breaks.
- Useful for research contexts where maximal, short-term GH elevation is the goal.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →Frequently Asked Questions
Continuous or frequent GHS-R1a agonism triggers rapid receptor downregulation—the pituitary reduces GHS-R1a expression and/or desensitizes downstream signaling in response to chronic stimulation. This is a natural homeostatic mechanism to prevent excessive GH release. Cycling (4–8 week breaks) allows receptors to upregulate and restore sensitivity. Ipamorelin desensitizes more slowly, likely due to lower absolute GHS-R1a occupancy, making it better for sustained use.
Elevated cortisol is expected and dose-dependent. Over a 2–4 week cycle, the cortisol elevation is unlikely to cause lasting harm, especially if cycles are followed by adequate breaks. However, anyone with hypertension, metabolic syndrome, or a history of mood disorders should be cautious. Baseline and end-of-cycle cortisol testing helps assess individual sensitivity. Longer cycles (8+ weeks) or very high doses warrant closer monitoring and consultation with a healthcare provider.
Partial mitigation is possible—dose variation or rotating between Hexarelin and other GHRPs (e.g., Hexarelin 2 weeks, then ipamorelin 4 weeks) can slow desensitization somewhat. However, it cannot be prevented entirely. The most practical approach is to accept that Hexarelin is a 2–4 week tool, maximize its use during that window, then switch to ipamorelin or take a break to let receptors recover.
Hexarelin produces stronger GH pulses, which theoretically should translate to greater muscle gain. However, formal human studies comparing the two for body composition are absent. Community reports are mixed—some users report superior strength and size gains with Hexarelin short-term bursts, while others find ipamorelin superior for lean mass gain over longer cycles due to its lower side effects and sustainable use. For muscle gain specifically, ipamorelin cycled for 8–12 weeks may actually outperform 2–4 weeks of Hexarelin due to cumulative IGF-1 elevation and training consistency.
Administer both in the same injection at the same time—both working simultaneously on their respective receptor pathways (ghrelin and GHRH) produces a synergistic GH pulse. Typical dose is 100 mcg Hexarelin + 100 mcg CJC-1295 (no DAC), 1–3x daily. This stack produces the highest GH pulses available but also maximizes cortisol elevation, so strict cycle discipline (2–3 weeks on, 6–8 weeks off) is even more critical. Only recommended for experienced researchers.
Receptor sensitivity (GHS-R1a) begins recovering after 2–4 weeks of abstinence, though complete restoration can take 6–8 weeks or longer. Most researchers wait at least 4–6 weeks before restarting Hexarelin to ensure adequate GH response recovery. Some use conservative protocols: 2 weeks Hexarelin on, 8 weeks off, repeat. Others rotate to ipamorelin for 4–8 weeks during Hexarelin break periods, then return to Hexarelin. Experimenting with your own cycles helps identify the optimal on/off pattern for your physiology.